Yang Luo

Key Laboratory Of Radiopharmaceuticals
Beijing, 100875, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics.

Dual-Chelator conjugates for [68Ga]Ga- and [177Lu]Lu-based PSMA Radiotheranostics.

Journal: Bioorganic chemistry

Published: June 01, 2026

First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia.

First-in-human study of a novel bifunctional PET tracer [68Ga]Ga-DOTA-NI-FAPI-04 targeting FAP and hypoxia.

Journal: European journal of nuclear medicine and molecular imaging

Published: August 12, 2025

First-in-Human PET Imaging of Prostate Cancer Using [68Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [68Ga]Ga-AZ-NI-093.

First-in-Human PET Imaging of Prostate Cancer Using [68Ga]Ga-AZ-093 and Its Nitroimidazole-Conjugated Derivative [68Ga]Ga-AZ-NI-093.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: June 23, 2025

PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC).

PSMA and SSTR2 Dual-Targeting Theranostic Agents for Neuroendocrine-Differentiated Prostate Cancer (NEPC).

Journal: Journal of medicinal chemistry

Published: January 10, 2025

Development of [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention.

Development of [68Ga]Ga/[177Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention.

Journal: Journal of medicinal chemistry

Published: December 23, 2024

68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer.

68Ga/177Lu-Labeled Bivalent Agents for Targeting Hypoxia and PSMA-Binding in Prostate Cancer.

Journal: Journal of medicinal chemistry

Published: July 29, 2024

Novel [68Ga/177Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy.

Novel [68Ga/177Lu]Ga/Lu-AZ-093 as PSMA-Targeting Agent for Diagnosis and Radiotherapy.

Journal: Molecular pharmaceutics

Published: June 10, 2024

[68Ga]Ga-HBED-CC-FAPI Derivatives with Improved Radiolabeling and Specific Tumor Uptake.

[68Ga]Ga-HBED-CC-FAPI Derivatives with Improved Radiolabeling and Specific Tumor Uptake.

Journal: Molecular pharmaceutics

Published: March 21, 2023

In vivo and in vitro binding of [125 I]I-R-(+)-TISCH: A dopamine D1 receptor ligand for studying pancreatic β-cell mass.

In vivo and in vitro binding of [125 I]I-R-(+)-TISCH: A dopamine D1 receptor ligand for studying pancreatic β-cell mass.

Journal: Journal of labelled compounds & radiopharmaceuticals

Published: July 08, 2022

68Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma.

68Ga-labelled-exendin-4: New GLP1R targeting agents for imaging pancreatic β-cell and insulinoma.

Journal: Nuclear medicine and biology

Published: July 31, 2021

Showing 1-10 of 10

Last Updated: 09/26/2026